Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2022 | Current biomarker testing guidelines for colorectal cancer

John Strickler, MD, Duke Cancer Center, Durham, NC, provides an overview of standard biomarker testing guidelines in the United States for colorectal cancer. Clinicians often look for KRAS, NRAS, BRAF and HER2 mutations and whilst HER2 mutations may not benefit from EFGR inhibitors, off-label HER2 inhibitors may benefit for patients with HER2 mutations. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.